191 related articles for article (PubMed ID: 12240824)
1. US drug industry bans expensive freebies for MDs, Canada raises fines.
Sibbald B
CMAJ; 2002 Sep; 167(5):522. PubMed ID: 12240824
[No Abstract] [Full Text] [Related]
2. Direct-to-consumer advertising of prescription drugs: balancing benefits and risks, and a way forward.
Kravitz RL; Bell RA
Clin Pharmacol Ther; 2007 Oct; 82(4):360-2. PubMed ID: 17851573
[No Abstract] [Full Text] [Related]
3. The drug war.
Meyer CR
Minn Med; 2000 Jan; 83(1):2, 57. PubMed ID: 10680422
[No Abstract] [Full Text] [Related]
4. World's first nonprofit drug company launched.
Cassels A
CMAJ; 2003 Sep; 169(6):590. PubMed ID: 12975232
[No Abstract] [Full Text] [Related]
5. Regulating manufacturer-affiliated communication in the information age.
Schulman KA; Abernethy DR; Rathore SS; Woosley RL
Clin Pharmacol Ther; 1999 Jun; 65(6):593-7. PubMed ID: 10391664
[No Abstract] [Full Text] [Related]
6. Litigation plays protective role--and is part of the problem.
Kennett JD
Mo Med; 2007; 104(1):12-3. PubMed ID: 17410818
[No Abstract] [Full Text] [Related]
7. The future sponsorship of CME in Canada: industry, government, physicians or a blend?
Marlow B
CMAJ; 2004 Jul; 171(2):150-1. PubMed ID: 15262885
[No Abstract] [Full Text] [Related]
8. Doctors don't fall for the hard sell.
Randerson J
New Sci; 2003 Jun; 178(2401):10. PubMed ID: 14686412
[No Abstract] [Full Text] [Related]
9. Merck pays $1bn penalty in relation to promotion of rofecoxib.
Tanne JH
BMJ; 2011 Nov; 343():d7702. PubMed ID: 22123916
[No Abstract] [Full Text] [Related]
10. The leadership role of general practice in public health: advocating a ban of direct-to-consumer advertising of prescription drugs in New Zealand. 'Possums in the headlights?'.
Toop L; Richards D; Dowell T
Br J Gen Pract; 2003 Apr; 53(489):342-5. PubMed ID: 12879848
[No Abstract] [Full Text] [Related]
11. Prescription drug expenditures rising--too fast?
CMAJ; 2005 May; 172(10):1261, 1263. PubMed ID: 15883389
[No Abstract] [Full Text] [Related]
12. The pharmaceutical industry: friend or foe?
Niebyl JR
Am J Obstet Gynecol; 2008 Apr; 198(4):435-9. PubMed ID: 18395035
[No Abstract] [Full Text] [Related]
13. An assessment of direct-to-consumer advertising of prescription drugs.
Calfee JE
Clin Pharmacol Ther; 2007 Oct; 82(4):357-60. PubMed ID: 17851572
[TBL] [Abstract][Full Text] [Related]
14. US drug companies paid $15bn in fines for fraudulent marketing in past five years.
Tanne JH
BMJ; 2010 Dec; 341():c7360. PubMed ID: 21177361
[No Abstract] [Full Text] [Related]
15. The death of common sense.
Trachtman H
Am J Bioeth; 2003; 3(3):W31-W32. PubMed ID: 14594484
[No Abstract] [Full Text] [Related]
16. Marketing drugs: debating the real cost. Concern about close ties between doctors and pharmaceutical firms are prompting new financial disclosure laws and education efforts.
Brand R
State Legis; 2008 Sep; 34(8):26-9. PubMed ID: 18754159
[No Abstract] [Full Text] [Related]
17. Serono pays $44m to settle promotion of multiple sclerosis drug.
Tanne JH
BMJ; 2011 May; 342():d2922. PubMed ID: 21558361
[No Abstract] [Full Text] [Related]
18. The physician and the pharmaceutical industry: both must keep the patient's interests at heart.
Ravindran GD
Issues Med Ethics; 1999; 7(1):21-2. PubMed ID: 16320467
[No Abstract] [Full Text] [Related]
19. To sell their drugs, companies increasingly rely on doctors.
Hensley S; Martinez B
Wall St J (East Ed); 2005 Jul; ():A1,A2. PubMed ID: 16134281
[No Abstract] [Full Text] [Related]
20. Prescription drug marketing: bribing health care workers?
Margolis RE
Healthspan; 1991 Jan; 8(1):18-20. PubMed ID: 10109337
[No Abstract] [Full Text] [Related]
[Next] [New Search]
